Phio Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Bob Bitterman

Chief Executive Officer (CEO)

US$172.9k

Compensación total

Porcentaje del salario del CEO	18.4%
Permanencia del CEO	less than a year
Participación del CEO	0.2%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	6.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Bob Bitterman en comparación con los beneficios de Phio Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	US$173k	US$32k	-US$11m
Sep 30 2022	n/a	n/a	-US$12m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$13m
Dec 31 2021	US$78k	n/a	-US$13m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$10m
Dec 31 2020	US$45k	n/a	-US$9m
Sep 30 2020	n/a	n/a	-US$9m
Jun 30 2020	n/a	n/a	-US$9m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	US$64k	n/a	-US$9m
Sep 30 2019	n/a	n/a	-US$8m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	n/a	n/a	-US$7m
Dec 31 2018	US$53k	n/a	-US$7m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$9m
Mar 31 2018	n/a	n/a	-US$9m
Dec 31 2017	US$36k	n/a	-US$12m
Sep 30 2017	n/a	n/a	-US$15m
Jun 30 2017	n/a	n/a	-US$15m
Mar 31 2017	n/a	n/a	-US$14m
Dec 31 2016	US$38k	n/a	-US$11m

Compensación vs. Mercado: Bob($USD172.93K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD418.12K).

Compensación vs. Ingresos: Bobha aumentado mientras la empresa no es rentable.

CEO

Bob Bitterman (71 yo)

less than a year

Permanencia

US$172,926

Compensación

Mr. Robert J. Bitterman, also known as Bob, serves as Chairman at Phio Pharmaceuticals Corp. since 2012 and has been its President and Chief Executive Officer since February 2023. Mr. Bitterman served as...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Bitterman	President	10.8yrs	US$172.93k	0.19% $ 10.1k
Geert Cauwenbergh	Director	11yrs	US$129.86k	0.18% $ 9.6k
Patricia Bradford	Independent Director	less than a year	US$42.29k	sin datos
James Griffin	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
Curtis Lockshin	Independent Director	10yrs	US$47.36k	0.11% $ 5.9k
Pamela Pavco	Member of Scientific Advisory Board	5.9yrs	sin datos	sin datos
Rolf Kiessling	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
Robert Ferrara	Lead Independent Director	3.5yrs	US$57.99k	0.17% $ 8.8k
Jonathan Freeman	Independent Director	5.8yrs	US$39.86k	0.11% $ 5.9k

6.2yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de 44R0 se considera experimentada (6.2 años de antigüedad promedio).

Phio Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023

Phio Pharmaceuticals Corp. Announces Board Appointments

Phio Pharmaceuticals Corp., Annual General Meeting, Aug 09, 2022

Phio Pharmaceuticals Corp. Announces Management Changes

Phio Pharmaceuticals Corp. Announces the Appointment of Patricia A. Bradford to Its Board of Directors

Recent updates

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

Phio Pharmaceuticals Corp. Presents Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

Phio Pharmaceuticals Corp. Announces Addition of Clinical Trial Sites At Banner Md Anderson Cancer Center, the George Washington University, and Integrity Research

Phio Pharmaceuticals Corp. Announces Patent Granted by Uspto, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

Phio Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

Phio Pharmaceuticals Corp. Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Phio Pharmaceuticals Corp. Announces the Presentation of New Preclinical Data At the 38Th Annual Meeting of the Society for Immunotherapy of Cancer

Phio Pharmaceuticals Corp. Presents New Data for Targeting of BRD4 with its INTASYL Compound PH-894

Phio Pharmaceuticals Corp. Announces Dosing of First Patient in Collaborative Clinical Trial with Agonox, Inc. and Providence Cancer Institute

Phio Pharmaceuticals Corp., Annual General Meeting, Jul 20, 2023

Phio Pharmaceuticals Corp. announced that it expects to receive $3.000002 million in funding

Phio Pharmaceuticals Corp Presents Preclinical Study Showing INTASYL Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells

Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas

Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Phio Pharmaceuticals Corp. Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Announces New Clinical Program to Study PH-762 for the Treatment of Cutaneous Squamous Cell Carcinoma

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer on November 10th and 11th

Phio Pharmaceuticals Corp. Announces Board Appointments

Phio Pharmaceuticals Corp. Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T Cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference

Phio Pharmaceuticals Discloses Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Phio Pharmaceuticals Corp., Annual General Meeting, Aug 09, 2022

Phio Pharmaceuticals Corp. Presents New Data Demonstrating PH-894 Enhances Activity of Her2-Car T Cells At ASGCT 2022

Phio Pharmaceuticals Corp. Announces Management Changes

Phio Pharmaceuticals Corp. Announces the Appointment of Patricia A. Bradford to Its Board of Directors

Phio Pharmaceuticals Corp. Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at AACR Annual Meeting 2022

Phio Pharmaceuticals Corp. Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial for PH-762 to Treat Melanoma

Phio Pharmaceuticals Presents Data at ESMO 2021 Demonstrating Persistent Anti-Tumor Immunity with INTASYL Dual-Targeting PD-1 and BRD4

Phio Pharmaceuticals Presents New in Vivo Data At the 2021 Asco Annual Meeting Showing Dual-Targeting Intasyl Offers Increased Efficacy and Safety Potential over Other Therapeutic Approaches

Phio Pharmaceuticals Presents Positive In Vivo Data at ASGCT Showing PH-762 Significantly Enhanced Antitumor Efficacy of HER2-Targeted CAR-T Cells

Phio Pharmaceuticals and AgonOx Inc. Announces Collaboration on Clinical Development of Novel T Cell-Based Cancer Immunotherapies

Phio Pharmaceuticals Corp. has completed a Follow-on Equity Offering in the amount of $7.684001 million.

Phio Pharmaceuticals Corp. announced that it has received $14.001908 million in funding

Phio Pharmaceuticals Corp. announced that it expects to receive $14.002049 million in funding

Phio Pharmaceuticals Corp. Announces Positive in Vivo Data on Combination PD-1 and TIGIT Checkpoint Blockade with INTASYL in a Single Therapeutic for Cancer Treatment